These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30138470)

  • 1. Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.
    Cariou A; Rouzier R; Baffert S; Soilly AL; Hequet D
    PLoS One; 2018; 13(8):e0202385. PubMed ID: 30138470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study.
    Héquet D; Huchon C; Soilly AL; Asselain B; Berseneff H; Trichot C; Combes A; Alves K; Nguyen T; Rouzier R; Baffert S
    PLoS One; 2019; 14(7):e0210917. PubMed ID: 31291250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 34-item Supportive Care Needs Survey and 8-item breast module French versions (SCNS-SF34-Fr and SCNS-BR8-Fr) in breast cancer patients.
    Brédart A; Kop JL; Griesser AC; Zaman K; Panes-Ruedin B; Jeanneret W; Delaloye JF; Zimmers S; Jacob A; Berthet V; Fiszer C; Dolbeault S
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):450-9. PubMed ID: 22571471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.
    Arfi A; Baffert S; Soilly AL; Huchon C; Reyal F; Asselain B; Neffati S; Rouzier R; Héquet D
    BMJ Open; 2018 May; 8(5):e020276. PubMed ID: 29776920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The patient-breast cancer care pathway: how could it be optimized?
    Baffert S; Hoang HL; Brédart A; Asselain B; Alran S; Berseneff H; Huchon C; Trichot C; Combes A; Alves K; Koskas M; Nguyen T; Roulot A; Rouzier R; Héquet D
    BMC Cancer; 2015 May; 15():394. PubMed ID: 25963161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
    Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
    Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness analysis of two breast cancer screening modalities in Shanghai, China].
    Mo M; Zheng Y; Liu G; Fang H; Zhang X; Zhai L; Chen Y; Lyu L; Zhu J; Luo J; Zhang L; Cao Z; Xu W; Shao Z
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):944-51. PubMed ID: 26887627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
    Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
    J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and cost-effectiveness issues in breast cancer treatment.
    Hillner BE
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
    J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
    Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
    PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability and validity of the Japanese version of the Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34-J).
    Okuyama T; Akechi T; Yamashita H; Toyama T; Endo C; Sagawa R; Uchida M; Furukawa TA
    Psychooncology; 2009 Sep; 18(9):1003-10. PubMed ID: 19177464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing psychological and supportive care needs in glioma patients - feasibility study on the use of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the Supportive Care Needs Survey Screening Tool (SCNS-ST9) in clinical practice.
    Renovanz M; Hickmann AK; Coburger J; Kohlmann K; Janko M; Reuter AK; Keric N; Nadji-Ohl M; König J; Singer S; Giese A; Hechtner M
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27774664
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.